129981-36-8 Usage
Uses
Used in Hypertension Treatment:
Sampatrilat is utilized as an antihypertensive agent for the management of high blood pressure. Its ability to inhibit ACE results in lowered blood pressure, making it a valuable treatment option for individuals suffering from hypertension.
Used in Congestive Heart Failure Management:
In the context of congestive heart failure, sampatrilat is employed as a therapeutic agent to improve blood flow and reduce the workload on the heart. By inhibiting ACE, it helps alleviate symptoms associated with this condition and supports heart function.
Used in Diabetic Nephropathy Management:
Sampatrilat is used as a potential treatment for diabetic nephropathy, a serious complication of diabetes that affects the kidneys. Its ACE inhibitory properties may help slow the progression of kidney disease and protect against further renal damage.
Used in Cardiovascular and Renal Protection:
Sampatrilat is being studied for its potential to protect against tissue damage caused by angiotensin II. This makes it a promising candidate for therapeutic use in various cardiovascular and renal conditions, where its ability to inhibit ACE could provide protective benefits and improve patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 129981-36-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,9,8 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 129981-36:
(8*1)+(7*2)+(6*9)+(5*9)+(4*8)+(3*1)+(2*3)+(1*6)=168
168 % 10 = 8
So 129981-36-8 is a valid CAS Registry Number.
InChI:InChI=1/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)23(34)28-18(15-22(32)33)16-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,34)(H,29,37)(H,32,33)(H,35,36)/t18-,20-,21-/m0/s1
129981-36-8Relevant articles and documents
The chemical development and scale-up of sampatrilat
Dunn, Peter J.,Hughes, Michael L.,Searle, Patricia M.,Wood, Albert S.
, p. 244 - 253 (2013/09/06)
The discovery and scale-up of two routes to sampatrilat are described. The first Chemical R and D route used a side product from another development project to accelerate drug supply and expedite the early development programme. The second, more efficient Chemical R and D route had the potential for commercialisation and used an environmentally friendly variant of the Baylis-Hillman reaction, and an asymmetric Michael addition as key steps. Full preparative details for the aminomethacrylate 4, a potentially useful chiral synthon, are given for the first time, along with full experimental details of the asymmetric Michael addition to make the chiral glutarate 5. Finally, a striking polymorph case history is described.
